Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | MAP3K12 | Q12852 | 6/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.34 |
| ▸ | SORD | Q00796 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38656893 | 0.93 | CNR2 (0.40) | CNR2MAP3K12GBA1DPP4HRH3 | |
| SCHEMBL38656894 | 0.93 | CNR2 (0.40) | CNR2MAP3K12GBA1DPP4HRH3 | |
| SCHEMBL17581297 | 0.89 | MAP3K12 (0.35) | CNR2MAP3K12DPP4SORD | |
| SCHEMBL38656409 | 0.79 | DPP4 (0.39) | CNR2MAP3K12GBA1DPP4HRH3 | |
| SCHEMBL30424030 | 0.72 | HRH3 (0.40) | CNR2HRH3 | |
| SCHEMBL9418612 | 0.71 | SORD (0.49) | SORD | |
| SCHEMBL23330850 | 0.69 | CNR2 (0.39) | CNR2MAP3K12HRH3PDE10A | |
| SCHEMBL27344417 | 0.69 | CYP11B1 (0.42) | CNR2DPP4HRH3 | |
| SCHEMBL26711595 | 0.69 | TRPV1 (0.42) | CNR2MAP3K12HRH3PDE10ASORD | |
| SCHEMBL25488830 | 0.69 | CNR2 (0.44) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010857-A | Selective mTOR inhibitor and preparation method and application thereof | 九江学院 | 2026-05-12 | — | — | CN | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| US-11584757-B2 | MK2 inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2023-02-21 | — | — | US | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3912981-A1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-11-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| EP-3193611-B1 | MK2 INHIBITORS AND USES THEREOF | CELGENE CAR LLC (BM) | 2021-03-24 | — | — | EP | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| CN-106998692-B | MK2 inhibitors and uses thereof | 西建卡尔有限责任公司 | 2020-09-08 | — | — | CN | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2017-04-27 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-9458175-B2 | MK2 inhibitors and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-10-04 | — | — | US | disclosed |
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-17 | — | — | US | disclosed |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114073-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CNR2 1189/4885MAP3K12 24/4885GBA1 3853/4885 |
| US-20160075720-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CNR2 1189/4885MAP3K12 24/4885GBA1 3853/4885 |
| US-11584757-B2 | MK2 inhibitors and uses thereof | MKNK2, DUSP2, MKNK1 | CNR2 1189/4885MAP3K12 24/4885GBA1 3853/4885 |
| US-20210053984-A1 | MK2 INHIBITORS AND USES THEREOF | MKNK2, DUSP2, MKNK1 | CNR2 1189/4885MAP3K12 24/4885GBA1 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.